RAME-HART Technology Helps Boost Vaccine Production in Emerging Markets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

RAME-HART Technology Helps Boost Vaccine Production in Emerging Markets


Emerging nations are particularly susceptible to seasonal and pandemic influenza outbreaks, but local vaccine manufacturers are challenged by infrastructure costs, competitive prices, and the lack of regulatory and technical expertise. RAME-HART, a global supplier of advanced, automated, egg inoculating and harvesting technologies, offers a semi-automatic line of technologies to meet regional needs, the company said in a press release.

“In developing regions with a limited infrastructure capacity, developers need optimized equipment and technologies capable of efficiently and cost-effectively producing vaccines,” said Ken Christiansen, president of RAME-HART, in the press release.  “Building up regional production in emerging nations is a central part of improving the global community’s access to vaccines during influenza outbreaks.”

RAME-HART’s series of single-station, semi-automatic machines covers critical production steps, including inoculation, candling, de-capping, harvesting, and fluid inspection. For manufacturers in developing markets working with limited infrastructure, the semi-automatic line fits into smaller facility footprints that rely on a flexible layout. Equipment can also be incorporated into larger operations to scale up production. Constructed with the same components found in RAME-HART’s fully automated lines, the semi-automatic machines deliver more vaccines through higher yields, accelerated egg handling, and reduced bio-burden.

The RAME-HART semi-automatic inoculator handles approximately 13,745 eggs per hour while the harvester and de-capper both process 12,600 eggs per hour. The company’s candling station employs patented inspection systems that identify and isolate egg irregularities, preventing harvest contamination. A sanitation station submerges inoculation needles into sanitation fluid and is drawn up between the punch and needle to ensure proper sterilization. These machines can also be modified to work with different size egg trays and customized requirements and can fulfill the varying production needs for human and veterinary influenza manufacturers.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here